Bevacizumab For Recurrent Ovarian Cancer:a Systematic Review And Clinical Analysis Of57Cases

Objective:Aims to discuss the treatment and prognosis of recurrent ovarian cancer.Methods:We electronically searched the Cochrane Library,MEDLINE, EMbase, CNKI,CBM,VIP.We also hand searched relevant conference proceedings. Randomized controlled trials comparing Bevacizumab versus other agents for recurrent ovarian cancer were included. According to the criteria of the Cochrane Handbook, two reviewers independently screened the studies, extracted and cross-checked the data, and assessed the methodological quality.Then statistics analysis was conducted by using RevMan5.2software..We retrospectively analyzed fifty-seven cases of recurrent ovarian cancer from January2009to December2012,which corresponded the standards. The efficacy of different treatment regimens were compared using logistic regression multivariate analysis.Using COX regression model for multivariate analysis.Results:Two RCTs including845patients were included. The results of Meta-analyses indicated that compared with conventional chemotherapy alone, BV plus conventional chemotherapy could prolong the PFS.The trials found no statistically significant difference in overall survival between people who received BV plus conventional chemotherapy compared to those who received conventional chemotherapy alone.The treatment of57patients of recurrent ovarian cancer into TP group,PIE group, other groups (Gemcitabine, Doxorubicin, monotherapy or in combination with other), efficiency were53.1%,.40.0%,50.0%respectively; There was no statistically significant difference of curative effect between different chemotherapy regimens, options of different regimens influence on survival time, there was no significant differences. Disease-free interval and recurrence of the number associated with overall survival after recurrence Conclusion:Second-line chemotherapy takes some effects in recurrent ovarian cancer.Bevacizumab combination with conventional chemotherapy is a direction of treatment of recurrent ovarian cancer.have positive effect on patients with recurrent ovarian cancer.